Portage Biotech (PRTG) Competitors $7.85 -0.18 (-2.24%) Closing price 08/26/2025 03:59 PM EasternExtended Trading$7.55 -0.30 (-3.82%) As of 08/26/2025 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRTG vs. AKTX, CLSD, MURA, JATT, SNYR, BTAI, MAAQ, DYAI, KZR, and MIRAShould you be buying Portage Biotech stock or one of its competitors? The main competitors of Portage Biotech include Akari Therapeutics (AKTX), Clearside Biomedical (CLSD), Mural Oncology (MURA), JATT Acquisition (JATT), Synergy CHC (SNYR), BioXcel Therapeutics (BTAI), Mana Capital Acquisition (MAAQ), Dyadic International (DYAI), Kezar Life Sciences (KZR), and MIRA Pharmaceuticals (MIRA). These companies are all part of the "pharmaceutical products" industry. Portage Biotech vs. Its Competitors Akari Therapeutics Clearside Biomedical Mural Oncology JATT Acquisition Synergy CHC BioXcel Therapeutics Mana Capital Acquisition Dyadic International Kezar Life Sciences MIRA Pharmaceuticals Portage Biotech (NASDAQ:PRTG) and Akari Therapeutics (NASDAQ:AKTX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation. Which has stronger valuation and earnings, PRTG or AKTX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPortage BiotechN/AN/A-$6.77M-$41.65-0.19Akari TherapeuticsN/AN/A-$19.79MN/AN/A Do analysts rate PRTG or AKTX? Akari Therapeutics has a consensus price target of $5.00, indicating a potential upside of 481.40%. Given Akari Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Akari Therapeutics is more favorable than Portage Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Portage Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Akari Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer PRTG or AKTX? In the previous week, Portage Biotech and Portage Biotech both had 1 articles in the media. Portage Biotech's average media sentiment score of 1.88 beat Akari Therapeutics' score of 1.87 indicating that Portage Biotech is being referred to more favorably in the media. Company Overall Sentiment Portage Biotech Very Positive Akari Therapeutics Very Positive Which has more risk & volatility, PRTG or AKTX? Portage Biotech has a beta of 0.24, indicating that its stock price is 76% less volatile than the S&P 500. Comparatively, Akari Therapeutics has a beta of 0.22, indicating that its stock price is 78% less volatile than the S&P 500. Do institutionals & insiders believe in PRTG or AKTX? 13.4% of Portage Biotech shares are owned by institutional investors. Comparatively, 5.1% of Akari Therapeutics shares are owned by institutional investors. 38.1% of Akari Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is PRTG or AKTX more profitable? Portage Biotech's return on equity of 0.00% beat Akari Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Portage BiotechN/A N/A N/A Akari Therapeutics N/A -78.03%-31.62% SummaryPortage Biotech beats Akari Therapeutics on 6 of the 10 factors compared between the two stocks. Get Portage Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for PRTG and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRTG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRTG vs. The Competition Export to ExcelMetricPortage BiotechMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.42M$3.07B$5.73B$9.74BDividend YieldN/A2.26%3.95%4.07%P/E Ratio-0.1920.5230.3326.09Price / SalesN/A352.87423.38106.20Price / CashN/A44.2437.7259.08Price / Book-9.948.139.796.67Net Income-$6.77M-$54.08M$3.27B$265.43M7 Day Performance-4.96%4.48%3.65%3.36%1 Month Performance37.00%3.64%3.83%0.39%1 Year Performance22.85%7.34%32.34%19.43% Portage Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRTGPortage Biotech1.0289 of 5 stars$7.85-2.2%N/A+22.3%$8.42MN/A-0.196Positive NewsAKTXAkari Therapeutics3.047 of 5 stars$0.98-1.9%$5.00+409.7%-76.9%$31.57MN/A0.009Positive NewsCLSDClearside Biomedical2.6747 of 5 stars$0.40-5.8%$4.20+947.4%-60.9%$31.48M$4.17M-1.0830News CoveragePositive NewsMURAMural Oncology2.9303 of 5 stars$1.78-2.5%$12.00+576.1%-39.4%$30.75MN/A-0.21119JATTJATT AcquisitionN/A$1.74+4.8%N/A-49.1%$30.02MN/A0.003High Trading VolumeSNYRSynergy CHC4.3591 of 5 stars$3.24-6.9%$10.00+208.6%+2,200.0%$29.79M$33.70M8.5340Gap DownBTAIBioXcel Therapeutics4.5442 of 5 stars$4.90-13.7%$39.75+711.9%-53.7%$29.72M$2.27M-0.3990Gap DownMAAQMana Capital AcquisitionN/A$3.63-9.8%N/A-38.6%$29.49MN/A0.001DYAIDyadic International3.4164 of 5 stars$0.80+0.7%$6.00+649.1%-37.6%$28.95M$3.49M-4.217Positive NewsKZRKezar Life Sciences3.6826 of 5 stars$3.90+1.0%$9.00+130.8%-41.7%$28.55M$7M-0.4060MIRAMIRA Pharmaceuticals3.0149 of 5 stars$1.42-4.4%$17.00+1,101.4%-34.1%$27.27MN/A-2.922 Related Companies and Tools Related Companies Akari Therapeutics Alternatives Clearside Biomedical Alternatives Mural Oncology Alternatives JATT Acquisition Alternatives Synergy CHC Alternatives BioXcel Therapeutics Alternatives Mana Capital Acquisition Alternatives Dyadic International Alternatives Kezar Life Sciences Alternatives MIRA Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRTG) was last updated on 8/27/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredChase, Bank of America, Wells Fargo Preparing for BIG ChangeThanks to this brand-new law #S.1582 signed by President Trump… Jeff Brown believes the largest banks in Am...Brownstone Research | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Portage Biotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Portage Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access